Long-term durability of PSA failure-free survival after radiotherapy for localized prostate cancer.

Purpose: To determine the durability of prostate-specific antigen (PSA) progression-free survival beyond 5 years in patients biochemically free of relapse 5 years after external beam radiotherapy (EBRT).

Methods And Materials: This study identified 328 men treated with EBRT to the prostate who were biochemically (American Society for Therapeutic Radiology and Oncology definition) disease free 5 years after treatment. The median follow-up was 7.

Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases.

Purpose: To assess whether failure to maintain local control (LC) of prostate cancer after radiation therapy results in a higher incidence of distant metastasis (DM).

Patients And Methods: From 1972 to 1999, 1,469 patients with clinically localized prostate cancer were treated with radical radiation therapy. Disease outcome was retrospectively reviewed for all patients with more than 2 years of follow-up.

Freedom from castration: an alternative end point for men with localized prostate cancer treated by external beam radiation therapy.

Purpose: Androgen deprivation therapy (ADT) is frequently given to men with localized prostate cancer. This study was designed to determine what proportion of men require subsequent ADT if their localized prostate cancer is first treated by radiation.

Methods And Materials: A retrospective review of the outcome of 768 men with T1-4NxM0 prostate cancer treated with external beam radiation at a single institution from 1988 to 1995.

Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer.

Objectives: To evaluate the outcomes of patients with muscle-invasive Stage T2-4a bladder carcinoma managed by transurethral surgery and concurrent chemoradiation.

Methods: A total of 190 patients were treated on institutional prospective protocols using concurrent cisplatin-containing chemotherapy and radiotherapy after rigorous transurethral resection of the bladder tumor. Patients were re-evaluated by repeated biopsy and urine cytologic analysis after 40 Gy, with the initial tumor response guiding subsequent therapy.

Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factors.

Objectives: To determine the probability of biochemical control for patients treated with salvage irradiation and identify prognostic factors associated with successful salvage. The optimal management of prostate cancer in patients with an elevated prostate-specific antigen (PSA) level after radical prostatectomy remains unclear.

Methods: We reviewed the records of 54 patients with node-negative prostate cancer treated with radiotherapy alone between 1991 and 1998 for isolated biochemical relapse after prostatectomy.

Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy.

Purpose: The long natural history of early stage prostate cancer is well recognized and a conservative approach to the treatment of elderly men is often encouraged. We assessed the ability of patients and physicians to adhere to a policy of watchful waiting in the prostate specific antigen (PSA) era.

Materials And Methods: We retrospectively reviewed the records of all 199 men with stages T1-2 prostate cancer and PSA less than 20 ng.

The prevalence of congenital orthopaedic anomalies in a rural community.

A rural Indian population of 50,055 was studied for the detection of congenital orthopaedic anomalies by a door-to-door survey. An incidence of 2.25 cases per 1000 population was found.